Breakthrough in engineered bacteria is a game-changer for biomedical applications
Researchers in the Department of Chemical Engineering have developed a new method for engineering bacteria that can be leveraged to improve biomedical applications such as drug delivery, cancer therapy, anti-inflammatory treatments, and vaccine development.
The international research group, led by Professor Yilan Liu, developed a process that enables bacteria to secrete bacterial membrane vesicles (BMVs). BMVs are nanosized bubble-shaped structures naturally released by bacteria. They have significant potential as tools for the development of a variety of therapeutics.
Currently, the adoption of BMVs has been hindered by low production yields under natural conditions. The technique established by Liu resulted in a 140-fold increase in the secretion of BMVs.
"This advancement in bacterial engineering has the potential to be a transformative platform for next-generation vaccines, therapeutics, and nutrient delivery," says Liu. "This new process could profoundly impact global health by making biomedical treatments more efficient, accessible, and affordable."